Menu

COPD

This study aims to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with symptomatic COPD, with a history of COPD exacerbations.

Key Study Information:

  • Treatment Area:

    COPD

  • Study Type:

    Interventional

  • Study Aim:

    A study to discover whether a new investigational medication (Tozorakimab) could help reduce the number of exacerbations for people with COPD.

  • Recruitment Target:

    30+ patients with symptomatic COPD

Join this study Right Arrow

Speak to our study support specialist for more information on this study.

10 minutes to participate in this study

  • 1
  • 2
  • 3
  • 4

Step One

Practice - Select a study

uMed supports multiple studies sponsored by commercial and academic institutions.

Your practice can choose a study via our website or dedicated web application.

Step Two

Practice - Review & Approve Eligible Patients

uMed runs a study specific search to identify potential participants.

uMed searches are compatible with EMIS or SystmOne. The results of this search are available to your practice in our web application for sign-off.

Previous

Step Three

uMed - Patient Contact

Once approved, we manage patient contact on your behalf via SMS, email and/or letter.

We provide a dedicated study support line for all patient enquiries to minimise incoming calls to your practice.

For most studies, between 10-30% of patients engage with our outreach.

Previous

Step Four

Patient - Consents to Join Study

Congratulations! You've empowered your patients to participate in vital clinical research that is most relevant for them.

Once the study concludes, we will share results and patient feedback with you so that you can see the impact of your participation. Any revenue generated from commercial studies is shared with your practice.

Previous

Not yet registered with uMed? Join over 400 GP Practices across the UK within the uMed Research Network and take part in the COPD study. Join the uMed Research Network.

More about COPD

This is a Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with symptomatic COPD, with a history of COPD exacerbations.

Register your interest in this study

 

Fill in the below form and a member of our team will be in touch to discuss next steps to participate in this study.

    Study name

    Practice name

    Your name

    Your role

    Email

    Phone number